T1	outcome-Measure 688 722	pathologic complete response (pCR)
T3	total-participants 842 845	188
T4	intervention 21 66	neoadjuvant chemotherapy with zoledronic acid
T6	control-participants 865 867	95
T7	intervention-participants 902 904	93
T8	outcome 924 927	DFS
T9	outcome 932 948	overall survival
T10	control-participants 966 968	92
T11	intervention-participants 973 975	88
T12	cv-cont-mean 1008 1014	5.15 y
T13	iv-cont-mean 1019 1025	5.38 y
T14	outcome 1045 1057	3-y DFS rate
T15	cv-bin-percent 1062 1067	84.6%
T16	iv-bin-percent 1088 1093	90.8%
T17	outcome 1207 1215	pCR rate
T18	cv-bin-percent 1289 1294	70.6%
T19	iv-bin-percent 1302 1307	94.1%
T2	outcome-Measure 758 781	clinical response rates
T5	outcome-Measure 783 816	rate of breast-conserving surgery
T20	outcome-Measure 818 824	safety
T21	outcome-Measure 830 833	DFS
T22	outcome 1363 1366	DFS
